• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Catalent Acquires Delphi Genetics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Almac Group

    test company saurabh

    Adare Pharma Solutions

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Syngene

    Aphena Pharma Solutions

    Alcami

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Final Frontier

    A look at contract bioprocessing and PAT/QbD

    The Final Frontier
    Related CONTENT
    • Lonza Expands Solid Small Molecule Services
    • CDMO Recro Strengthens Leadership Team
    • Jubilant Biosys, Yale Form Research Alliance
    • Targeted Protein Degradation at Syngene
    • Catalent Divests Blow-Fill-Seal Sterile CDMO Business
    Emil W. Ciurczak, DoraMaxx Consulting06.12.18
    The idea of process control for bioprocesses was introduced by Rick Cooley (Eli Lilly) for insulin production and purification. The quality control (QC) lab was constructed and the plant was, quite literally, built around the lab. Holes were drilled into the wall(s) where the fermentation tanks and purification columns were located. He eventually designed and built the first real-time process chromatography equipment for his own use. Since Lilly is a pharmaceutical entity, not an instrument company, he sought a vendor willing to supply similar equipment. [For those of you who haven’t had the “privilege” of bumping against the “not invented here,” a.k.a. “NIH” attitude of instrument companies, you have had a long, happy life.] Eventually, he persuaded Dionex (now part of Thermo-Fisher) to produce and sell them to him, allowing him to do the first biotech PAT work.

    Please keep in mind that “real-time” for biopharma is nowhere near the time scales as for small molecule production—with the exception of API synthesis, but that is for another day. Where we look for millisecond scan/analysis speeds for tablet production, twenty minutes for a measurement/analysis in bioproduction is fine. Simply stated, a 12, 24, 36, or even 72-hour fermentation time scarcely needs data produced every second or two—even with inexpensive storage space for data, the retrieval headaches would be phenomenal. Five, ten or even 15-minutes between measurements is quite fine, especially considering that current “wet” chemical tests used in biotech analyses can take hours to glean the data necessary (i.e., time to add more nutrients, change stir rate, or quench the reaction to harvest the end product).

    Back in the 1980s, when I suggested that fermentations could be followed by near-infrared, the “classically-trained” biochemists told me the spectra were too amorphous and they couldn’t see specific peaks and things like ammonium (nitrate) wouldn’t show up, etc. So, 30-years ago, I suggested a simple experiment; insert the probe and scan over time. When the scans no longer changed, the reaction had stopped and samples could be taken for “normal” testing. Why do this? Bioreactions are not as well defined and “normal” chemical reactions. Depending on the starting material, inoculation culture(s), speed of agitation, temperature variations, and such, the reaction could take +/- 25% to reach feed points or end points. Having an SOP that tells the operator to sample at set times can introduce problems: if the reaction is anaerobic, oxygen could enter; the operator could be exposed to the bacterium; and lastly, taking extra time-consuming assays is a waste of time and materials. Taking samples when your spectrometer signals is far smarter.

    Obviously, much progress has been made since then. Numerous determinations have been generated and are used on a routine basis. A typical example of real time analysis is NIRS being used to monitor a bioreactor in situ during a CHO (Chinese hamster ovary) cell culture reaction. By inserting the proper probe, readings may be taken as often or seldom as empirical results dictate. Some simultaneous measurements include but are not limited to glutamine (Figure 1), lactate (Figure 2), glucose (Figure 3), ammonia, titer, methionine, and glutamate. Other reported predictions are pH, dissolved oxygen, biomass, and osmolity. Certainly, other tests could be developed, as well.


     


    Figure 1. Glutamine Concentration: circular points = wet analysis, solid points = NIR prediction


    Figure 2. Lactate Production: Solid points = NIR; circles = Wet Analysis


    Figure 3. Glucose Concentration: solid points = NIR; white circles = wet analysis

    What, then, is the purpose of spending all that money on real-time testing equipment NIRS, Raman, HPLC/UPLC (Ultra-high Pressure or Precision LC)? Well, for one reason, most contract manufacturing organizations (CMOs) and contract research organizations (CROs) do not have unlimited time, money, or personnel. While a larger organization—originator, often owned by a large company with deep pockets—may have “excess” capacity and a smaller number of products, CMOs are smaller, leaner, and have a high number of products to turn over in a set amount of time. The traditional manner of bioprocessing is both time and labor intensive, and not conducive to a smaller CMO starting a program. Add to that the expertise available to a typical traditional biopharma company.

    What do I mean by “available expertise?” We may simply compare the disciplines in a traditional larger, established small molecule company with a macromolecular producing bio-pharma plant. The small molecule company has organic and analytical chemists, including R&D and QC; pharmacists, including formulators and clinicians; engineers; often an instrument group; and an array of instruments, including chromatography, spectroscopy, and physical measuring devices to call upon. The bioprocess companies? In most instances, they are run and staffed by people trained in the biological sciences: biochemists, microbiologists, bacteriologists, and so forth.

    In the small molecule company, there are numerous steps from the initial synthesis of the drug candidate, through clinical testing, formulation, pilot plant to final production. Any number of technical disciplines “touch” the small molecule and any number of analytical techniques are used to measure these steps. To move from lab-based testing to process testing and control is simply a matter of upgrading existing instrumentation and software. The largest hurdle is management buy-in—convincing them of a real ROI—in most cases. The argument is, “We’re making a profit and been doing things this way for 50 years; why change now?”

    In the macromolecular world, we have a completely different set of hurdles to jump. In a nutshell, homogeneity of backgrounds is the main problem. That is, at every level—discovery through final production—we have the same disciplines addressing every problem. The analysis of the first small amount of some bioproduct is, inevitably, the same as for a 1,000-liter reactor. As a consequence, there is no “advantage-of-scale” solutions sought. When a small molecule QC lab is confronted with dozens of lots of tablets to be analyzed, the manager/analysts seek alternate methods of analysis. Simply moving from HPLC to UPLC could shorten an individual analysis from 10-15 minutes to one-to-three minutes—a tenfold speed advantage is realized.

    With traditional bioassays, the development time is seldom able to be sped up proportionately to a wet chemical analysis. When presented with an alternative technology, a small molecule chemist is more likely to at least be open to considering change. Traditional, or current, biological assays are, due to natural growth times, seldom able to be “hurried.” As a consequence, traditional bio-analysts have little experience with more rapid/alternative technologies. Framed in the picture of growth in an agar plate, technologies such as near-infrared, Raman, and such do not seem to be alternatives to be studied.

    However, with the advent of rapid bio-assays, the “why bother when we still have to wait for the plates to develop’ ecus no longer holds water. At this point, allow me to emphasize one important point: any assay (prediction) performed by NIRS, Raman, or any other non-traditional method can also be confirmed since these technologies are non-destructive! Unlike traditional comparisons (e.g., a new HPLC method to existing one), where a sample is divided between two sample preps, then assayed (paired t-test), a spectroscopic method samples the exact same material as the traditional (compendial) method. BOTH may be run for confirmation for as long as necessary to appease quality assurance (QA) personnel.

    Having stated that, why is it less specific for us to determine biomass by NIRS than measure the energy needed to turn the mixing blades? I have seen numerous cases where the power curve—energy needed to keep paddles at the same speed—is used to follow the growth of biomass. The power of Chemometrics, used with NIRS can be at least as accurate, while having the benefit of actual spectra to examine and file. Figure 4, for example, follows the titer of the CHO growth versus conventional measurements.


    Figure 4. Following the Titer in a CHO growth medium

    All these measurements mentioned so far are, of course, organic and are expected to have NIR spectra. What about inorganics? Figure 5 shows the determination of ammonia during the CHO reaction over 300 hours. While NH4+ doesn’t have a spectacular spectrum, its hydrogen bonding affects the overall spectrum of the mix, allowing for an algorithm to follow it in real time. While it does not have a characteristic spectrum, the resolution, low noise, and reproducibility of a good NIR system, the use of Chemometrics allows for the monitoring of things such as NH4+, dissolved O2, and the like.


    Figure 5. Level of ammonia throughout a 300 hour (CHO) run

    The next comment could well be, “Why bother speeding up the fermentation when downstream clean-up takes so long, anyway?” While that is a topic for a later column, let me say, “Spoiler alert: NIRS can be used here, as well.” For the time being, let’s just say that monitoring the bioprocess can allow for better sampling times and allows an operator to be aware of problems between formal sample times. As a bonus, a more rapid turnover of equipment optimizes its use, essentially allowing the production of more batches without adding hardware. 


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • production
    • merck
    • quality
    • Development
    Suggested For You
    Lonza Expands Solid Small Molecule Services Lonza Expands Solid Small Molecule Services
    CDMO Recro Strengthens Leadership Team CDMO Recro Strengthens Leadership Team
    Jubilant Biosys, Yale Form Research Alliance Jubilant Biosys, Yale Form Research Alliance
    Targeted Protein Degradation at Syngene Targeted Protein Degradation at Syngene
    Catalent Divests Blow-Fill-Seal Sterile CDMO Business Catalent Divests Blow-Fill-Seal Sterile CDMO Business
    Angelini Pharma Acquires Arvelle Therapeutics for $960M Angelini Pharma Acquires Arvelle Therapeutics for $960M
    Aurinia and Lonza Expand Manufacturing Partnership Aurinia and Lonza Expand Manufacturing Partnership
    Catalent Invests $10M in Isolator Capabilities to Expand Micronization Catalent Invests $10M in Isolator Capabilities to Expand Micronization
    Sterling Makes Strategic Investment in ADC Bio Sterling Makes Strategic Investment in ADC Bio
    Inhaled Drug Delivery Technology Trends Inhaled Drug Delivery Technology Trends
    Cell & Gene Therapy Supply Chain: Early Preparation is Key Cell & Gene Therapy Supply Chain: Early Preparation is Key
    Cambrex Expands API Mfg. Capacity in Charles City Cambrex Expands API Mfg. Capacity in Charles City
    Evotec SE Expands UK Campus Evotec SE Expands UK Campus
    Flamma, Gilead Continue Mfg. Partnership for Veklury Flamma, Gilead Continue Mfg. Partnership for Veklury
    DCAT Elects New President DCAT Elects New President

    Related Columns

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Analytical Services | Laboratory Testing
      Re-Open Your Tool Chest

      Re-Open Your Tool Chest

      There’s no longer an excuse NOT to start “PAT-ing” your products
      Emil W. Ciurczak, DoraMaxx Consulting 07.15.19


    • Bioanalytical Services
      Getting PAT into Bioprocessing CMOs

      Getting PAT into Bioprocessing CMOs

      The Good, the Bad, and the “Whatever”
      Emil W. Ciurczak, DoraMaxx Consulting 06.13.19

    • Analytical Services | Laboratory Testing
      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry
      Emil W. Ciurczak, DoraMaxx Consulting 03.06.19

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18


    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18

    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18

    • Analytical Services | Laboratory Testing
      We Need to Get Back to Basics

      We Need to Get Back to Basics

      In life, and the lab, the calculator/computer is a blessing and a curse!
      Emil W. Ciurczak, DoraMaxx Consulting 05.08.18


    • Chemistry | Laboratory Testing
      When Your Product is Neither a Liquid or a Solid

      When Your Product is Neither a Liquid or a Solid

      And you need to analyze/control it, in real time.
      Emil W. Ciurczak, DoraMaxx Consulting 01.30.18

    • Analytical Services
      Finding the “Missing Link”

      Finding the “Missing Link”

      Outsourcing and the supply chain
      Emil W. Ciurczak, DoraMaxx Consulting 10.11.17

    • Bioanalytical Services

      21st Century Technologies for Bioprocessing Control

      A closer look at the manufacture of biomolecules
      Emil W. Ciurczak, DoraMaxx Consulting 06.06.17


    • Bioanalytical Services
      Current Trends in Analytical Testing

      Current Trends in Analytical Testing

      Improved analytical methods continues to be a current need for nearly every aspect of biopharma manufacturing
      Eric S. Langer, BioPlan Associates 05.09.17

    • Analytical Services | Laboratory Testing
      Analytical Equipment Technology for the 21st Century

      Analytical Equipment Technology for the 21st Century

      A look at some more toys available for CMOs, CROs and generics to boost their analytical capabilities
      Emil W. Ciurczak, DoraMaxx Consulting 05.09.17

    • Analytical Services
      Quality Risk Management

      Quality Risk Management

      It’s not just for the big guys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 04.03.17

    Trending
    • Century Therapeutics Significantly Expands Capabilities
    • Catalent Acquires Delphi Genetics
    • Sanofi And Translate Bio Expand Vaccine Collaboration
    • RotaChrom Technologies Partners With Cyclolab
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    Breaking News
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    • Catalent Acquires Delphi Genetics
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Previon, Spectrum Solutions Partner to Deliver At-Home COVID-19 Test
    NTT Research, Japanese Entity to Collaborate on Cardiovascular Disease Interventions
    Global Peripheral Intravenous Catheter Market to Reach $7.5 Billion by 2027
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    ACG Launches ACG Laboratories
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Afro Sheen Launches New Brand Initiatives
    Neopac Introduces Lightweight Plastic Tube
    Estée Lauder Companies Increases Investment in Deciem Beauty Group Inc.
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Ontex Reports Lower Revenues
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    OrthoGrid Releases New Hip Replacement Software
    Nexus Spine Announces Availability of Spine Surgery Implants
    FDA OKs Brainlab's Loop-X Mobile Imaging Robot, Cirq Robotic Alignment Module
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login